You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameColestipol
Accession NumberDB00375  (APRD00884)
TypeSmall Molecule
GroupsApproved
DescriptionHighly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels. [PubChem]
Structure
Thumb
Synonyms
Colestipolum
Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane
Epichlorohydrin-tetraethylenepentamine polymer
External Identifiers
  • U 26597 A
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Colestidgranule, for suspension5 g/5goralPharmacia and Upjohn Company1977-04-04Not applicableUs
Colestidtablet1 g/1oralPharmacia And Upjohn Company Llc1994-07-19Not applicableUs
Colestid Granulesgranules5 goralPfizer Canada Inc1985-12-31Not applicableCanada
Colestid Orange Granulesgranules5 goralPfizer Canada Inc1995-12-31Not applicableCanada
Colestid Tablets 1 Gtablet1 goralPfizer Canada Inc1995-12-31Not applicableCanada
Colestipol Hydrochloridegranule, for suspension5 g/5goralGreenstone LLC1977-04-04Not applicableUs
Colestipol Hydrochloridetablet1 g/1oralGreenstone LLC1994-07-19Not applicableUs
Colestipol Hydrochloridetablet1 g/1oralPhysicians Total Care, Inc.2007-02-28Not applicableUs
Colestipol Hydrochloridetablet1 g/1oralCarilion Materials Management1994-07-19Not applicableUs
Flavored Colestidgranule, for suspension5 g/7.5goralPharmacia and Upjohn Company1977-04-04Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Colestipol Hydrochloridetablet, film coated1 g/1oralImpax Generics2006-10-24Not applicableUs
Colestipol Hydrochloridesuspension5 g/1oralImpax Generics2006-05-02Not applicableUs
Colestipol Hydrochloridesuspension5 g/1oralImpax Generics2006-05-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CholestabylNot Available
LestidPfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Colestipol hydrochloride
37296-80-3
ThumbNot applicableDBSALT001058
Categories
UNIIK50N755924
CAS number26658-42-4
WeightAverage: 281.826
Monoisotopic: 281.19823825
Chemical FormulaC11H28ClN5O
InChI KeyInChIKey=GMRWGQCZJGVHKL-UHFFFAOYSA-N
InChI
InChI=1S/C8H23N5.C3H5ClO/c9-1-3-11-5-7-13-8-6-12-4-2-10;4-1-3-2-5-3/h11-13H,1-10H2;3H,1-2H2
IUPAC Name
(2-aminoethyl)[2-({2-[(2-aminoethyl)amino]ethyl}amino)ethyl]amine; 2-(chloromethyl)oxirane
SMILES
ClCC1CO1.NCCNCCNCCNCCN
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as epoxides. These are compounds containing a cyclic ether with three ring atoms(one oxygen and two carbon atoms).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassEpoxides
Sub ClassNot Available
Direct ParentEpoxides
Alternative Parents
Substituents
  • Oxacycle
  • Secondary amine
  • Ether
  • Oxirane
  • Secondary aliphatic amine
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Primary aliphatic amine
  • Amine
  • Alkyl halide
  • Alkyl chloride
  • Aliphatic heteromonocyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor use, as adjunctive therapy to diet, for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet.
PharmacodynamicsCholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating absorption. A major portion of the bile acids secreted is reabsorbed from the intestines and returned via the portal circulation to the liver, thus completing the enterohepatic cycle. Only very small amounts of bile acids are found in normal serum. Colestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces. This nonsystemic action results in a partial removal of the bile acids from the enterohepatic circulation, preventing their reabsorption. Since colestipol hydrochloride is an anion exchange resin, the chloride anions of the resin can be replaced by other anions, usually those with a greater affinity for the resin than the chloride ion.
Mechanism of actionColestipol is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7-(alpha)-hydroxylase, is upregulated, which increases the conversion of cholesterol to bile acids. This causes an increased demand for cholesterol in the liver cells, resulting in the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme, hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase, and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood, resulting in decreased serum LDL-C levels. Serum triglyceride levels may increase or remain unchanged. The end result is increased clearance of LDL-cholesterol from the blood with decreased serum LDL-cholesterol.
Related Articles
AbsorptionNot absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot applicable (not hydrolyzed by digestive enzymes and not absorbed).
Metabolism

Not applicable (not hydrolyzed by digestive enzymes and not absorbed).

Route of eliminationColestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces. In humans, less than 0.17% of a single 14C-labeled colestipol hydrochloride dose is excreted in the urine when given following 60 days of chronic dosing of 20 grams of colestipol hydrochloride per day. The increased fecal loss of bile acids due to colestipol hydrochloride administration leads to an increased oxidation of cholesterol to bile acids.
Half lifeNot Available
ClearanceNot Available
ToxicityOral LD50 in rats is > 1000 mg/kg. Symptoms of overdose may include eye irritation, constipation, abdominal cramps, nausea, vomiting, diarrhea, and hypersensitivity. However, as colestipol is not absorbed, the risk of systemic toxicity is low.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9221
Blood Brain Barrier+0.8825
Caco-2 permeable-0.5102
P-glycoprotein substrateSubstrate0.6506
P-glycoprotein inhibitor INon-inhibitor0.9435
P-glycoprotein inhibitor IINon-inhibitor0.956
Renal organic cation transporterNon-inhibitor0.6803
CYP450 2C9 substrateNon-substrate0.8931
CYP450 2D6 substrateNon-substrate0.7534
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.7178
CYP450 2C9 inhibitorNon-inhibitor0.8515
CYP450 2D6 inhibitorNon-inhibitor0.8411
CYP450 2C19 inhibitorNon-inhibitor0.7634
CYP450 3A4 inhibitorNon-inhibitor0.8919
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9404
Ames testAMES toxic0.9093
CarcinogenicityNon-carcinogens0.6451
BiodegradationNot ready biodegradable0.9346
Rat acute toxicity2.5333 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.508
hERG inhibition (predictor II)Non-inhibitor0.7601
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Impax laboratories inc
Packagers
Dosage forms
FormRouteStrength
Granule, for suspensionoral5 g/5g
Granulesoral5 g
Tabletoral1 g
Suspensionoral5 g/1
Tabletoral1 g/1
Tablet, film coatedoral1 g/1
Granule, for suspensionoral5 g/7.5g
Prices
Unit descriptionCostUnit
Colestid 90 5 gm Packets Box252.5USD box
Colestid 30 5 gm Packets Box81.11USD box
Colestid Flavored 5 gm/7.5 gm Packets3.29USD packet
Colestid 5 g Powder Packet1.04USD packet
Colestid Orange 5 g Powder Packet1.04USD packet
Colestid 1 gm tablet0.86USD tablet
Colestipol hcl 1 gm tablet0.66USD tablet
Colestid 5 gm Granules0.33USD gm
Colestid Flavored 5 gm Granules0.31USD gm
Colestid flavored granules0.3USD g
Colestid 1 g Tablet0.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5490987 No1993-02-132013-02-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP-2.206Not Available
Predicted Properties
PropertyValueSource
logP-2.5ChemAxon
pKa (Strongest Basic)9.81ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area88.13 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity56.04 m3·mol-1ChemAxon
Polarizability23.97 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Lednicer, D. and Peery,C.Y.; US. Patent 3,803,237; April 9, 1974; assigned to The Upjohn Co.

General ReferencesNot Available
External Links
ATC CodesC10AC02
AHFS Codes
  • 24:06.04
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (53.5 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneColestipol can cause a decrease in the absorption of 4-Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.
AceclofenacColestipol can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcenocoumarolColestipol can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetyldigitoxinColestipol can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetylsalicylic acidColestipol can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AdapaleneColestipol can cause a decrease in the absorption of Adapalene resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlclometasoneColestipol can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
AldosteroneColestipol can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmcinonideColestipol can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmiodaroneThe bioavailability of Amiodarone can be decreased when combined with Colestipol.
AntipyrineColestipol can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ApremilastColestipol can cause a decrease in the absorption of Apremilast resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Colestipol.
AzapropazoneColestipol can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
AzelastineColestipol can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BalsalazideColestipol can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Beclomethasone dipropionateColestipol can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.
BendroflumethiazideColestipol can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
BenoxaprofenColestipol can cause a decrease in the absorption of Benoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
BetamethasoneColestipol can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
BezafibrateColestipol can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
BromfenacColestipol can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
BudesonideColestipol can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
BumetanideColestipol can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CarprofenColestipol can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CastanospermineColestipol can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CelecoxibColestipol can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Colestipol.
ChloroquineColestipol can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ChlorothiazideColestipol can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ChlorthalidoneColestipol can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidColestipol can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideColestipol can cause a decrease in the absorption of Ciclesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofibrateColestipol can cause a decrease in the absorption of Ciprofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clobetasol propionateColestipol can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClocortoloneColestipol can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClofibrateColestipol can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClonixinColestipol can cause a decrease in the absorption of Clonixin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateColestipol can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
D-LimoneneColestipol can cause a decrease in the absorption of D-Limonene resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferasiroxThe serum concentration of Deferasirox can be decreased when it is combined with Colestipol.
DehydroepiandrosteroneColestipol can cause a decrease in the absorption of Dehydroepiandrosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.
dehydroepiandrosterone sulfateColestipol can cause a decrease in the absorption of dehydroepiandrosterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeslanosideColestipol can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.
DesoximetasoneColestipol can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Desoxycorticosterone acetateColestipol can cause a decrease in the absorption of Desoxycorticosterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DexamethasoneColestipol can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dexamethasone isonicotinateColestipol can cause a decrease in the absorption of Dexamethasone isonicotinate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DiclofenacColestipol can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
DicoumarolColestipol can cause a decrease in the absorption of Dicoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.
DiflorasoneColestipol can cause a decrease in the absorption of Diflorasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
DiflunisalColestipol can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.
DifluocortoloneColestipol can cause a decrease in the absorption of Difluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
DifluprednateColestipol can cause a decrease in the absorption of Difluprednate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DigitoxinColestipol can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DigoxinColestipol can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DiltiazemColestipol can cause a decrease in the absorption of Diltiazem resulting in a reduced serum concentration and potentially a decrease in efficacy.
DroxicamColestipol can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
EpirizoleColestipol can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy.
EquileninColestipol can cause a decrease in the absorption of Equilenin resulting in a reduced serum concentration and potentially a decrease in efficacy.
EquilinColestipol can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy.
EstroneColestipol can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Etacrynic acidColestipol can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
EtanerceptColestipol can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ethyl biscoumacetateColestipol can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
EtodolacColestipol can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.
EtofenamateColestipol can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy.
EtofibrateColestipol can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
EtoricoxibColestipol can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Evening primrose oilColestipol can cause a decrease in the absorption of Evening primrose oil resulting in a reduced serum concentration and potentially a decrease in efficacy.
exisulindColestipol can cause a decrease in the absorption of exisulind resulting in a reduced serum concentration and potentially a decrease in efficacy.
EzetimibeColestipol can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy.
FenbufenColestipol can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy.
FenofibrateColestipol can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
FenoprofenColestipol can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
FloctafenineColestipol can cause a decrease in the absorption of Floctafenine resulting in a reduced serum concentration and potentially a decrease in efficacy.
FludrocortisoneColestipol can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.
FlumethasoneColestipol can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
FlunisolideColestipol can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
FlunixinColestipol can cause a decrease in the absorption of Flunixin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluocinolone AcetonideColestipol can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluocinonideColestipol can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluocortoloneColestipol can cause a decrease in the absorption of Fluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluorometholoneColestipol can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluprednideneColestipol can cause a decrease in the absorption of Fluprednidene resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluprednisoloneColestipol can cause a decrease in the absorption of Fluprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
FlurandrenolideColestipol can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.
FlurbiprofenColestipol can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluticasone furoateColestipol can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluticasone PropionateColestipol can cause a decrease in the absorption of Fluticasone Propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.
FurosemideColestipol can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
GemfibrozilColestipol can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy.
HMPL-004Colestipol can cause a decrease in the absorption of HMPL-004 resulting in a reduced serum concentration and potentially a decrease in efficacy.
HydrochlorothiazideColestipol can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
HydrocortisoneColestipol can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.
HydroflumethiazideColestipol can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
IbuprofenColestipol can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
IbuproxamColestipol can cause a decrease in the absorption of Ibuproxam resulting in a reduced serum concentration and potentially a decrease in efficacy.
IcatibantColestipol can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.
IndapamideColestipol can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
IndomethacinColestipol can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
IndoprofenColestipol can cause a decrease in the absorption of Indoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
IsoxicamColestipol can cause a decrease in the absorption of Isoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
KebuzoneColestipol can cause a decrease in the absorption of Kebuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.
KetoprofenColestipol can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
KetorolacColestipol can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.
LeflunomideThe serum concentration of the active metabolites of Leflunomide can be reduced when Leflunomide is used in combination with Colestipol resulting in a loss in efficacy.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Colestipol.
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Colestipol.
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Colestipol.
LomitapideColestipol can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy.
LornoxicamColestipol can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
LoxoprofenColestipol can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
LumiracoxibColestipol can cause a decrease in the absorption of Lumiracoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium salicylateColestipol can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.
MasoprocolColestipol can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Meclofenamic acidColestipol can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
MedrysoneColestipol can cause a decrease in the absorption of Medrysone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mefenamic acidColestipol can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
MelengestrolColestipol can cause a decrease in the absorption of Melengestrol resulting in a reduced serum concentration and potentially a decrease in efficacy.
MeloxicamColestipol can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
MesalazineColestipol can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MetamizoleColestipol can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethotrexateColestipol can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethyclothiazideColestipol can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethylprednisoloneColestipol can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
MetolazoneColestipol can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
MometasoneColestipol can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolate mofetilColestipol can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colestipol.
NabumetoneColestipol can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.
NaftifineColestipol can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.
NaproxenColestipol can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.
NCX 4016Colestipol can cause a decrease in the absorption of NCX 4016 resulting in a reduced serum concentration and potentially a decrease in efficacy.
NepafenacColestipol can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.
NiacinColestipol can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Niflumic AcidColestipol can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
NimesulideColestipol can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.
OlopatadineColestipol can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.
OlsalazineColestipol can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
OrgoteinColestipol can cause a decrease in the absorption of Orgotein resulting in a reduced serum concentration and potentially a decrease in efficacy.
OuabainColestipol can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.
OxaprozinColestipol can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.
OxyphenbutazoneColestipol can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ParamethasoneColestipol can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ParecoxibColestipol can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
PhenindioneColestipol can cause a decrease in the absorption of Phenindione resulting in a reduced serum concentration and potentially a decrease in efficacy.
PhenprocoumonColestipol can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.
PhenylbutazoneColestipol can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
PimecrolimusColestipol can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.
PiretanideColestipol can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.
PirfenidoneColestipol can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.
PiroxicamColestipol can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
PolythiazideColestipol can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Colestipol.
PrednicarbateColestipol can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.
PrednisoloneColestipol can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
PrednisoneColestipol can cause a decrease in the absorption of Prednisone resulting in a reduced serum concentration and potentially a decrease in efficacy.
PregnenoloneColestipol can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
PropacetamolColestipol can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Colestipol.
PTC299Colestipol can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy.
QuinethazoneColestipol can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
RaloxifeneColestipol can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.
ResveratrolColestipol can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.
RimexoloneColestipol can cause a decrease in the absorption of Rimexolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
RofecoxibColestipol can cause a decrease in the absorption of Rofecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
SalicylamideColestipol can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Salicylic acidColestipol can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
SalsalateColestipol can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.
SeratrodastColestipol can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.
SRT501Colestipol can cause a decrease in the absorption of SRT501 resulting in a reduced serum concentration and potentially a decrease in efficacy.
SulfasalazineColestipol can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
SulindacColestipol can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.
SuprofenColestipol can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
TenoxicamColestipol can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
TepoxalinColestipol can cause a decrease in the absorption of Tepoxalin resulting in a reduced serum concentration and potentially a decrease in efficacy.
TeriflunomideThe serum concentration of Teriflunomide can be decreased when it is combined with Colestipol.
Thyroid, porcineThe serum concentration of Thyroid, porcine can be decreased when it is combined with Colestipol.
Tiaprofenic acidColestipol can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
TixocortolColestipol can cause a decrease in the absorption of Tixocortol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tolfenamic AcidColestipol can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
TolmetinColestipol can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.
TorasemideColestipol can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
TranilastColestipol can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.
TriamcinoloneColestipol can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
TrichlormethiazideColestipol can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trisalicylate-cholineColestipol can cause a decrease in the absorption of Trisalicylate-choline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ursodeoxycholic acidThe serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Colestipol.
ValdecoxibColestipol can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.
VancomycinThe therapeutic efficacy of Vancomycin can be decreased when used in combination with Colestipol.
WarfarinColestipol can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ZaltoprofenColestipol can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
ZileutonColestipol can cause a decrease in the absorption of Zileuton resulting in a reduced serum concentration and potentially a decrease in efficacy.
ZomepiracColestipol can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
  • Take with food.

Targets

1. Bile acids
Kind
Group
Organism
Human
Pharmacological action
yes
Actions
binder
References
  1. LaRosa JC: The mechanism of action of lipid-lowering drugs. Angiology. 1982 Sep;33(9):562-76. [PubMed:7125296 ]
  2. Farmer JA, Gotto AM Jr: Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin Endocrinol Metab. 1995 Oct;9(4):825-47. [PubMed:8593127 ]
  3. Reiner Z: Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol. 2010 Feb;24(1):19-28. doi: 10.1111/j.1472-8206.2009.00764.x. Epub 2009 Aug 14. [PubMed:19682080 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23